Cobenfy is also in phase 3 clinical testing ... currently in two phase 2 studies. It offers once-daily dosing, versus twice-daily with BMS' drug and, according to some assessments, could be ...

No signs of tolerance were seen after sub-chromic dosing and more than 30-fold safety ... perhaps most notably the failure of the Phase 3 trial of COBENFY as adjunctive treatment in schizophrenia?

3) Bristol Myers Squibb's Cobenfy (KarXT; xanomeline and trospium ... 13 antibody for atopic dermatitis that offers less frequent dosing than its two predecessors in the class, Sanofi/Regeneron's ...

Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in $27 million in net sales in the first three months of the year — beating Wall Street sales expectations and analyst predictions.

The drug was approved under the brand name Cobenfy. The approval of Cobenfy for schizophrenia broadens BMY’s portfolio and validates the acquisition of Karuna Therapeutics. Cobenfy represents ...

This growth was mainly driven by Opdivo, Breyanzi, Reblozyl, and Camzyos, along with the strong early launch of Cobenfy in the US. Bristol-Myers Squibb Company (NYSE:BMY)’s cash position ...

AbbVie Q1 sales rose 8.4% to $13.34 billion, and adjusted EPS grew 6.5% to $2.46, beating Wall Street estimates. Skyrizi sales jumped 70.5% to $3.43 billion, and Rinvoq sales climbed 57.2% to $1. ...

We recently published a list of the 30 Growing Dividend Stocks with Low PE Ratios.In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other ...

The company is advancing its growth strategy with a robust pipeline of therapies, especially its neuroscience drug, Cobenfy. Positive results from ongoing trials could significantly enhance the ...